Company: BLRX
Filing Date: 2025-03-31
Form Type: 20-F
Source: 0001178913-25-001123
Chunk: 0

Company: BioLineRx Ltd.
Filing Date: 2025-03-31
Form: 20-F
Item: Item 3
Chunk 0
---
ITEM 3. KEY INFORMATION

A. [Reserved]

B. Capitalization and Indebtedness

Not applicable.

C. Reasons for the Offer and Use of Proceeds

Not applicable.

D. Risk Factors

You should carefully consider the risks we describe below, in addition
to the other information set forth elsewhere in this Annual Report on Form 20-F, including our consolidated financial statements and the
related notes beginning on page F-1, before deciding to invest in our ordinary shares and ADSs. These material risks could adversely impact
our results of operations, possibly causing the trading price of our ordinary shares and ADSs to decline, and you could lose all or part
of your investment.

Summary Risk Factors

Investing in our ordinary shares involves a high degree of risk,
as fully described below. The principal factors and uncertainties that make investing in our ordinary shares risky include, among others:

Risks Related to Our Financial Condition and Capital Requirements

  We have incurred significant losses since inception and expect to incur additional losses in the future  
  and may never be profitable.                                                                             
 ───────────────────────────────────────────────────────────────────────────────────────────────────────────

  We cannot assure investors that our existing cash and investment balances will be sufficient to meet our  

  If we default under our secured loan agreement with BlackRock EMEA Venture and Growth Lending (previously         

  Management has concluded that there is substantial doubt about our ability to continue as a going concern,  

Risks Related to Our Business and Regulatory Matters

  We have earned limited commercialization revenues to date. We may never achieve profitability.  
 ──────────────────────────────────────────────────────────────────────────────────────────────────

  APHEXDA, or any other therapeutic candidate that may receive marketing approval in                                                        
  the future, may fail to achieve the degree of market acceptance by physicians, patients, third-party payors and others in the medical     
  community necessary for commercial success and the market opportunity for APHEXDA or any other therapeutic candidate may be smaller than  
  our estimates.                                                                                                                            
 ────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────

  If we or our collaborators are unable to obtain and/or maintain U. S. and/or foreign                                                              

  We and our collaborators may not obtain additional marketing approvals for motixafortide                     
  in other indications or initial approval for any other therapeutic candidates we may develop in the future.  
 ─────────────────────────────────────────